Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jaguar Health, Inc. - Common Stock
(NQ:
JAGX
)
2.500
-0.020 (-0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
June 30, 2025
Via
ACCESS Newswire
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
June 26, 2025
Via
Stocktwits
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
June 26, 2025
Via
ACCESS Newswire
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
June 25, 2025
Via
ACCESS Newswire
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
June 24, 2025
Via
ACCESS Newswire
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
June 23, 2025
Via
ACCESS Newswire
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
June 17, 2025
Via
ACCESS Newswire
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
June 11, 2025
Via
ACCESS Newswire
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
June 09, 2025
Via
ACCESS Newswire
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
June 09, 2025
Via
ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
June 06, 2025
Via
ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’
May 21, 2025
Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 21, 2025
Via
Benzinga
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 21, 2025
Via
ACCESS Newswire
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
May 20, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Thursday's After-Market Session
May 15, 2025
Via
Benzinga
Jaguar Health Reports First Quarter 2025 Financials
May 15, 2025
Via
ACCESS Newswire
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
May 14, 2025
Via
ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
May 08, 2025
Via
ACCESS Newswire
Earnings Scheduled For May 15, 2025
May 15, 2025
Via
Benzinga
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
May 07, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 30, 2025
Via
Benzinga
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
April 30, 2025
Via
ACCESS Newswire
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
April 29, 2025
Via
ACCESS Newswire
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
April 28, 2025
Via
ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
April 25, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Top stock movements in today's session.
April 25, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
April 25, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 24, 2025
Via
Benzinga
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
April 17, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.